Vestmark Advisory Solutions Inc. Boosts Holdings in Stryker Co. (NYSE:SYK)

Vestmark Advisory Solutions Inc. increased its holdings in Stryker Co. (NYSE:SYK) by 9.1% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,819 shares of the medical technology company’s stock after buying an additional 152 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Stryker were worth $655,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker in the 4th quarter worth about $25,000. Dunhill Financial LLC increased its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the 4th quarter worth about $30,000. BankPlus Trust Department bought a new stake in Stryker in the 4th quarter worth about $33,000. Finally, Darwin Wealth Management LLC bought a new stake in Stryker in the 3rd quarter worth about $36,000. 77.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SYK has been the subject of several research analyst reports. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. The Goldman Sachs Group boosted their price target on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $422.15.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Down 0.8 %

NYSE SYK opened at $379.28 on Friday. The stock’s 50 day moving average is $382.45 and its 200 day moving average is $372.99. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market cap of $144.73 billion, a PE ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm posted $3.46 EPS. Research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.